Nitrofurantoin revisited: A systematic review and meta-analysis of controlled trials

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 9, 2015, Pages 2456-2464

  Huttner, Angela ^a   Verhaegh, Els M ^b   Harbarth, Stephan ^a   Muller, Anouk E ^c   Theuretzbacher, Ursula ^d   Mouton, Johan W ^e,f  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

^d Center For Anti Infective Agents Vienna   (Austria)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antibacterial; Antibiotic; Efficacy; Toxicity; Urinary tract infections

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; COTRIMOXAZOLE; NITROFURANTOIN; ANTIINFECTIVE AGENT;

ADVERSE DRUG REACTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CONTROLLED CLINICAL TRIAL (TOPIC); DATA EXTRACTION; DRUG EFFICACY; HUMAN; INTERRATER RELIABILITY; META ANALYSIS; NONHUMAN; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT DURATION; URINARY TRACT INFECTION; CHEMICALLY INDUCED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROINTESTINAL DISEASE; PATHOLOGY; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

ANTI-INFECTIVE AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GASTROINTESTINAL DISEASES; HUMANS; NITROFURANTOIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84942196162     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv147     Document Type: Review

References (37)

1. Shah RR, Wade G. Reappraisal of the risk/benefit of nitrofurantoin: review of toxicity and efficacy. Adverse Drug React Acute Poisoning Rev 1989; 8: 183-201.
2. [AFSSAPS Practice recommendations for diagnosis and antibiotic therapy of adult community urinary tract infections]. Med Mal Infect 2008; 38 Suppl 3: S203-52.
3. Beckford-Ball J. Management of suspected bacterial urinary tract infection. Nurs Times 2006; 102: 25-6.
4. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-20.
5. van Pinxteren B, van Vliet SM, Wiersma TJ et al. [Summary of the practice guideline 'Urinary-tract infections' (second revision) from the Dutch College of General Practitioners]. Ned Tijdschr Geneeskd 2006; 150: 718-22.
6. Huttner A, Huttner B, Jones M et al. Antibiotic use in Veterans Affairs long-term-care facilities: a nationwide analysis using barcode medication administration data, 2007-2009. In: Abstracts of ID Week 2012, San Diego, CA, 2012. Abstract 724. Infectious Disease Society of America, Arlington, VA, USA.
7. Daneman N, Gruneir A, Newman A et al. Antibiotic use in long-term care facilities. J Antimicrob Chemother 2011; 66: 2856-63.
8. McOsker CC, Fitzpatrick PM. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. J Antimicrob Chemother 1994; 33 Suppl A: 23-30.
9. D'Arcy PF. Nitrofurantoin. Drug Intell Clin Pharm 1985; 19: 540-7.
10. Cunha BA. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. Med Clin N Am 2006; 90: 1089-107.
11. Sachs J, Geer T, Noell P et al. Effect of renal function on urinary recovery of orally administered nitrofurantoin. New Engl J Med 1968; 278: 1032-5.
12. Cunha BA. Nitrofurantoin-current concepts. Urology 1988; 32: 67-71.
13. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
14. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration, 2011. http://www.cochrane-handbook.org.
15. Gupta K, Hooton TM, Roberts PL et al. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 2007; 167: 2207-12.
16. Lopez-Carmona JM, Salazar-Lopez MA, Rodriguez-Moctezuma JR et al. [Acute cystitis in women with type 2 diabetes. Three antimicrobial schemes]. Rev Med Inst Mex Seguro Soc 2007; 45: 503-12.
17. Ernst EJ, Ernst ME, Hoehns JD et al. Women's quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment. Health Qual Life Outcomes 2005; 3: 45.
18. Gupta K, Hooton TM, Stamm WE. Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. J Antimicrob Chemother 2005; 56: 243-6.
19. Iravani A, Klimberg I, Briefer C et al. A trial comparing low-dose, shortcourse ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection. J Antimicrob Chemother 1999; 43 Suppl A: 67-75.
20. Hooton TM, Winter C, Tiu F et al. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA 1995; 273: 41-5.
21. Stein GE. Comparison of single-dose fosfomycin and a 7-day course of nitrofurantoin in female patients with uncomplicated urinary tract infection. Clin Ther 1999; 21: 1864-72.
22. Christiaens TC, DeMeyere M, Verschraegen G et al. Randomised controlled trial of nitrofurantoin versus placebo in the treatment of uncomplicated urinary tract infection in adult women. Br J Gen Pract 2002; 52: 729-34.
23. Kalowski S, Radford N, Kincaid-Smith P. Crystalline and macrocrystalline nitrofurantoin in the treatment of urinary-tract infection. New Engl J Med 1974; 290: 385-7.
24. Hailey FJ, Glascock HW Jr. Gastrointestinal tolerance to a new macrocrystalline form of nitrofurantoin: a collaborative study. Curr Ther Res Clin Exp 1967; 9: 600-5.
25. Sherigar JM, Fazio R, Zuang M et al. Autoimmune hepatitis induced by nitrofurantoin. The importance of the autoantibodies for an early diagnosis of immune disease. Clin Pract 2012; 2: e83.
26. Mulberg AE, Bell LM. Fatal cholestatic hepatitis and multisystem failure associated with nitrofurantoin. J Pediatr Gastroenterol Nutr 1993; 17: 307-9.
27. Slekovec C, Leroy J, Huttner A et al. When the precautionary principle disrupts 3 years of antibiotic stewardship: nitrofurantoin in the treatment of urinary tract infections. J Antimicrob Chemother 2014; 69: 282-4.
28. Sandegren L, Lindqvist A, Kahlmeter G et al. Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli. J Antimicrob Chemother 2008; 62: 495-503.
29. McCalla DR, Kaiser C, Green MH. Genetics of nitrofurazone resistance in Escherichia coli. J Bacteriol 1978; 133: 10-6.
30. Sanchez GV, Master RN, Karlowsky JA et al. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012; 56: 2181-3.
31. Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 2012; 39: 45-51.
32. Kothari A, Sagar V. Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study. J Infect Dev Ctries 2008; 2: 354-8.
33. Sire JM, Nabeth P, Perrier-Gros-Claude JD et al. Antimicrobial resistance in outpatient Escherichia coli urinary isolates in Dakar, Senegal. J Infect Dev Ctries 2007; 1: 263-8.
34. Lewis DA, Gumede LY, van der Hoven LA et al. Antimicrobial susceptibility of organisms causing community-acquired urinary tract infections in Gauteng Province, South Africa. S Afr Med J 2013; 103: 377-81.
35. Communicable Disease Prevention and Control Services, British Columbia Centre for Disease Control. Antimicrobial Resistance Trends in the Province of British Columbia 2011. http://www.bccdc.ca/NR/rdonlyres/4F04BB9C-A670-4A35-A236-CE8F494D51A3/0/AntimicrobialResistanceTrendsinBC_2011.pdf.
36. de Greeff SC, MoutonJW. NETHMAP 2013: Consumption of Antimicrobial Agents and Antimicrobial Resistance Among Medically Important Bacteria in the Netherlands. https://www.wageningenur.nl/upload_mm/7/8/9/52388c6c-858c-483c-b57d-227029fe778a_005738_Nethmap_2013%20def_web.pdf.
37. EARS-NET. http://www.ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/database/Pages/database.aspx.